Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
382,523,969
-
Total 13F shares
-
896,807,871
-
Share change
-
+106,851,363
-
Total reported value
-
$7,383,978,168
-
Put/Call ratio
-
81%
-
Price per share
-
$8.31
-
Number of holders
-
158
-
Value change
-
+$844,855,283
-
Number of buys
-
100
-
Number of sells
-
61
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q4 2021
As of 31 Dec 2021,
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) was held by
158 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
896,807,871 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, GENERAL ATLANTIC, L.P., BAILLIE GIFFORD & CO, Senator Investment Group LP, Anchorage Capital Group, L.L.C., ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., MORGAN STANLEY, and Sumitomo Mitsui Trust Holdings, Inc..
This page lists
158
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.